Hualan Biological Bacterin Inc.
Hualan Biological Vaccine Inc. engages in the research and development, production, and sale of vaccines and genetic engineering biological products in China. The company offers influenza vaccine (split virion), recombinant hepatitis B vaccine (hansenula polymorpha), meningococcal polysaccharide vaccine, influenza vaccine (split virion) quadrivalent, and meningococcal polysaccharide vaccine. It a… Read more
Hualan Biological Bacterin Inc. - Asset Resilience Ratio
Hualan Biological Bacterin Inc. (301207) has an Asset Resilience Ratio of 21.37% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how Hualan Biological Bacterin Inc.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Hualan Biological Bacterin Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.53 Billion | 21.37% |
| Total Liquid Assets | CN¥1.53 Billion | 21.37% |
Asset Resilience Insights
- Good Liquidity Position: Hualan Biological Bacterin Inc. maintains a healthy 21.37% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Hualan Biological Bacterin Inc. Industry Peers by Asset Resilience Ratio
Compare Hualan Biological Bacterin Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Hualan Biological Bacterin Inc. (2019–2024)
The table below shows the annual Asset Resilience Ratio data for Hualan Biological Bacterin Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 19.38% | CN¥1.46 Billion | CN¥7.52 Billion | -5.28pp |
| 2023-12-31 | 24.66% | CN¥1.97 Billion | CN¥8.00 Billion | +4.60pp |
| 2022-12-31 | 20.06% | CN¥1.42 Billion | CN¥7.08 Billion | +1.80pp |
| 2021-12-31 | 18.26% | CN¥825.82 Million | CN¥4.52 Billion | +5.84pp |
| 2020-12-31 | 12.41% | CN¥452.86 Million | CN¥3.65 Billion | +0.05pp |
| 2019-12-31 | 12.37% | CN¥221.90 Million | CN¥1.79 Billion | -- |